Author
Listed:
- Yang Yang
(Medical Research Council Laboratory of Molecular Biology)
- Yang Shi
(Medical Research Council Laboratory of Molecular Biology)
- Manuel Schweighauser
(Medical Research Council Laboratory of Molecular Biology)
- Xianjun Zhang
(Thermo Fisher Scientific)
- Abhay Kotecha
(Thermo Fisher Scientific)
- Alexey G. Murzin
(Medical Research Council Laboratory of Molecular Biology)
- Holly J. Garringer
(Indiana University School of Medicine)
- Patrick W. Cullinane
(University College London
University College London)
- Yuko Saito
(Metropolitan Institute of Gerontology)
- Tatiana Foroud
(Indiana University School of Medicine)
- Thomas T. Warner
(University College London
University College London)
- Kazuko Hasegawa
(Sagamihara National Hospital)
- Ruben Vidal
(Indiana University School of Medicine)
- Shigeo Murayama
(University of Osaka)
- Tamas Revesz
(University College London
University College London)
- Bernardino Ghetti
(Indiana University School of Medicine)
- Masato Hasegawa
(Metropolitan Institute of Medical Science)
- Tammaryn Lashley
(University College London
University College London)
- Sjors H. W. Scheres
(Medical Research Council Laboratory of Molecular Biology)
- Michel Goedert
(Medical Research Council Laboratory of Molecular Biology)
Abstract
Parkinson’s disease (PD) is the most common movement disorder, with resting tremor, rigidity, bradykinesia and postural instability being major symptoms1. Neuropathologically, it is characterized by the presence of abundant filamentous inclusions of α-synuclein in the form of Lewy bodies and Lewy neurites in some brain cells, including dopaminergic nerve cells of the substantia nigra2. PD is increasingly recognised as a multisystem disorder, with cognitive decline being one of its most common non-motor symptoms. Many patients with PD develop dementia more than 10 years after diagnosis3. PD dementia (PDD) is clinically and neuropathologically similar to dementia with Lewy bodies (DLB), which is diagnosed when cognitive impairment precedes parkinsonian motor signs or begins within one year from their onset4. In PDD, cognitive impairment develops in the setting of well-established PD. Besides PD and DLB, multiple system atrophy (MSA) is the third major synucleinopathy5. It is characterized by the presence of abundant filamentous α-synuclein inclusions in brain cells, especially oligodendrocytes (Papp-Lantos bodies). We previously reported the electron cryo-microscopy structures of two types of α-synuclein filament extracted from the brains of individuals with MSA6. Each filament type is made of two different protofilaments. Here we report that the cryo-electron microscopy structures of α-synuclein filaments from the brains of individuals with PD, PDD and DLB are made of a single protofilament (Lewy fold) that is markedly different from the protofilaments of MSA. These findings establish the existence of distinct molecular conformers of assembled α-synuclein in neurodegenerative disease.
Suggested Citation
Yang Yang & Yang Shi & Manuel Schweighauser & Xianjun Zhang & Abhay Kotecha & Alexey G. Murzin & Holly J. Garringer & Patrick W. Cullinane & Yuko Saito & Tatiana Foroud & Thomas T. Warner & Kazuko Has, 2022.
"Structures of α-synuclein filaments from human brains with Lewy pathology,"
Nature, Nature, vol. 610(7933), pages 791-795, October.
Handle:
RePEc:nat:nature:v:610:y:2022:i:7933:d:10.1038_s41586-022-05319-3
DOI: 10.1038/s41586-022-05319-3
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:610:y:2022:i:7933:d:10.1038_s41586-022-05319-3. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.